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Abstract
Background: Inflammation plays an important role in cardiac repair after myocardial infarction (MI). Nevertheless,
the systems-level characterization of inflammation proteins in MI remains incomplete. There is a need to
demonstrate the potential value of molecular network-based approaches to translational research. We investigated
the interplay of inflammation proteins and assessed network-derived knowledge to support clinical decisions after
MI. The main focus is the prediction of clinical outcome after MI.
Methods: We assembled My-Inflamome, a network of protein interactions related to inflammation and prognosis
in MI. We established associations between network properties, disease biology and capacity to distinguish
between prognostic categories. The latter was tested with classification models built on blood-derived microarray
data from post-MI patients with different outcomes. This was followed by experimental verification of significant
associations.
Results: My-Inflamome is organized into modules highly specialized in different biological processes relevant to
heart repair. Highly connected proteins also tend to be high-traffic components. Such bottlenecks together with
genes extracted from the modules provided the basis for novel prognostic models, which could not have been
uncovered by standard analyses. Modules with significant involvement in transcriptional regulation are targeted by
a small set of microRNAs. We suggest a new panel of gene expression biomarkers (TRAF2, SHKBP1 and UBC) with
high discriminatory capability. Follow-up validations reported promising outcomes and motivate future research.
Conclusion: This study enhances understanding of the interaction network that executes inflammatory responses
in human MI. Network-encoded information can be translated into knowledge with potential prognostic
application. Independent evaluations are required to further estimate the clinical relevance of the new prognostic
genes.
Background
Cardiovascular disease is a major cause of death world-
wide. Myocardial infarction (MI) often leads to heart
failure (HF), which makes MI a leading source of mor-
bidity and hospitalizations [1]. Different inflammation
biomarkers with diagnostic and prognostic applications
have been deployed in the clinical setting [2,3]. Post-MI
cell death triggers the activation of several complex
inflammatory processes to clear dead cells and initiate
heart tissue regeneration [4-7]. It has been suggested
that such a coordinated regulation is fundamental to
enable cardiac repair and recovery after MI [8]. C-reac-
tive protein (CRP) and other pro-inflammatory cytokines
are widely-applied biomarkers in the routine clinical set-
ting [2,6,9]. For example, CRP’s capacity to identify
patients with high risk of developing HF has been
demonstrated in different studies, including the Fra-
mingham Heart Study [10], though this can be achieved
at the expense of low specificity [2].
Notwithstanding the widely-accepted application of
different prognostic biomarkers after MI, including indi-
cators of inflammation, there is a need to provide new
insights into the complex mechanisms leading to HF. In
addition, currently there is no single biomarker capable
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MI outcome [2]. Standard research approaches have
been based on the analysis of differential expression of
putative biomarkers, using gene or protein expression
values [3,4,11]. The need to provide mechanistic under-
standing at a systems level, while improving the predic-
tive ability of candidate biomarkers, makes network-
based approaches a pertinent new research direction in
this clinical area. This strategy not only entails the
representation and analysis of networks of putative bio-
markers, but also benefits from the integration of multi-
ple sources of omic information.
The application of systems-driven approaches to dis-
covering prognostic biomarkers and understanding dis-
ease biology has received relatively more attention in
the areas of cancer and neurodegenerative diseases
[12-14]. We have previously demonstrated its potential
to guide new knowledge discovery in translational
research of MI [15-19]. For instance, we have estab-
lished quantitative connections between network topolo-
gical features, modularity and prognostic outcome in
post-MI [16]. Moreover, we have explored the prognos-
tic value of new biomarkers relevant to angiogenesis and
cardiac repair [15,18]. Based on these outcomes and the
lack of systems biology research of inflammation in the
specific context of MI, we set out to investigate a com-
prehensive set of inflammation-implicated protein inter-
actions and its potential prognostic value post-MI.
The main focus of this investigation was to predict clini-
cal outcome after MI, in particular left ventricular
dysfunction.
Objective
The objective of our investigation is three-fold:
1. To characterize a comprehensive compendium of
protein interactions relevant to inflammation and
(post-MI) HF, through the implementation of an
integrative biological network approach.
2. To establish qualitative and quantitative connec-
tions between network properties, disease biology
and prognostic outcomes.
3. To test the potential of new network-derived
prognostic biomarkers of post-MI ventricular
dysfunction.
Methods
Research framework
Our investigation required the integration and analysis
of multiples types of omic and clinical data, including
external public information repositories and data gener-
ated at our laboratory. Figure 1 synthesizes the main
phases and outputs of our research. First, using expert
Figure 1 Research framework and analytical pipeline
implemented.
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the context of inflammation and prognosis after MI. To
reduce bias towards well-characterized biomarkers and
to enable the discovery of new biological knowledge,
this list of traditional biomarkers was expanded into a
set of network seeds. This was accomplished by retriev-
ing other functionally- and phenotypically-related genes
from different public databases. These seeds were the
product of a gene prioritization, which was established
on the basis of their quantitative functional similarity to
the traditional biomarkers. We then interrogated multi-
ple protein-protein interaction (PPI) databases using the
seeds as query inputs. This resulted in the extraction of
their experimentally-validated PPIs in human, and the
construction of a global network of PPIs in the MI and
inflammation setting (My-Inflamome). This network was
analyzed on the basis of different topological features to
identify potential critical components and sub-networks.
The next phase aimed to answer the question of
whether (and how) network-based information could be
applied to aid in post-MI prognostic applications. More
specifically, we investigated whether the genes encoding
critical network components or involved in significant
molecular modules could be applied to distinguish
between post-MI clinical categories. To further demon-
strate this translational research application, we built
different classification systems based on microarray data
from a small set of clinically meaningful genes. Models
were evaluated using a standard cross-validation proce-
dure. Furthermore, an experimental follow-up, using
multiplex PCR, was conducted to assess opportunities
for future research. These methods are described in
more detail as follows.
My-Inflamome seeds
The initial set of well-investigated inflammation biomar-
kers included those commonly applied in clinical prac-
tice, as well as others discussed in review articles in the
post-MI context (Results) [2,3]. Genes functionally
related to these biomarkers were searched in different
public databases with the Endeavour system [20], which
has previously been applied to different disease network
investigations [16,21]. This is a gene prioritization task
in which the training set is represented by the set of
well-known biomarkers, and candidate genes originate
from whole-genome searches. Functional similarity
between candidate and training set genes is established
using different types of omic information, such as anno-
tation databases, gene sequences and public gene
expression datasets. Thus, functional relatedness is esti-
mated based on data source-specific similarity criteria. A
global, multi-source similarity score is computed for
each candidate gene across these resources, which is
then used to rank candidate genes. The reader is
referred to [21] for details about this gene search and
prioritization procedure. We concentrated on candidate
genes with global prioritization score, PS, equal to or
lower than 0.01. The union of the sets of retrieved can-
didate genes and the well-known biomarkers repre-
sented the seeds of My-Inflamome.
My-Inflamome construction
We obtained PPIs for the seeds using different public
PPI databases: DIP [22], IntAct [23] and MINT [24]
databases. These datasets have been shown to be com-
plementary with high interactome quality and coverage
[25]. We only retrieved PPIs validated in humans and
focused on immediate (direct) seed-protein interactions.
This aids in the reduction of the likelihood of retrieving
PPIs not significantly related to the post-MI domain
(false positives). The union of all retrieved PPIs defined
My-Inflamome. We visualized and analyzed it with
Cytoscape [26] and PolarMapper [27].
My-Inflamome analysis
In My-Inflamome, proteins and their pair-wise interac-
tions are graphically represented as network nodes and
edges respectively. We analyzed fundamental network
topological features at the node level: node degree and
traffic. The former refers to the number of edges asso-
ciated with a node. The latter, also referred to as
“betweeness centrality”, is the number of shortest paths
that go through the node, and which link any two other
nodes in the network.
A group of highly-interconnected nodes can be
defined as a “module”. A module may be identified
through network clustering, which meets specific statis-
tical analysis criteria as explained below. There are var-
ious statistical or topological features that can be used
to characterize the networks, its modules and individual
components. High traffic nodes indicate their “bottle-
neck” property, which has been correlated with different
biologically-meaningful features, including putative dis-
ease biomarkers and drug targets [28-30]. In another
study, we demonstrated the predictive potential of high
traffic nodes in a global PPI network to detect patients
with ventricular dysfunction [16].
Network modularity is another key topological prop-
erty previously linked to disease biology and biomarker
discovery [16,18,19,31]. A network module can be
defined as a highly-interconnected sub-network, whose
number of connections is larger than that expected
from randomly pairing its proteins. We applied a
“greedy” network clustering algorithm that maximizes a
modularity score, Q, defined as: Q=( n u m I M E / n u m E )-
(numIME/numE)random,w i t hnumIME and numE repre-
senting the number of edges in a module and the total
number of network edges respectively. We implemented
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analyzes with PolarMapper [27].
We characterized the resulting network modules on
the basis of their association with Gene Ontology (GO)
Biological Process (BP) and Cellular Component (CC)
annotations. We also examined statistically detectable
associations between microRNAs (miRNAs) and RNA
targets in each module, and which are annotated in the
miRBase database [32]. These associations were com-
puted through (two-tailed) Fisher’se x a c tt e s t sa n dc o r -
rected to account for multiple-hypothesis testing using
the Benjamini & Hochberg procedure. We concentrated
on associations with (corrected) P < 0.01. We completed
this functional characterization of modules with the
Fatigo tool, under the Babelomics (v4.1) platform [33].
The Statistica software was used for standard statistical
analysis [34].
Prognostic biomarker discovery
To investigate the prognostic potential of critical nodes
and modules, we examined the ability of their corre-
sponding genes to distinguish between poor and good
outcomes after MI (specified below). This was done on
(blood-derived) gene expression data generated by
microarray experiments at our laboratory (Gene Expres-
sion Omnibus, GEO, accession number: GSE11947)
[35]. These data were obtained from circulating white
blood cells, which play prominent roles in inflammation.
Thus, we hypothesized that these cells better reflect
inflammatory responses than secreted proteins. We first
sought high traffic nodes and network modules showing
strong differential expression capability, at the gene set
level, across good and poor clinical outcome. The latter
was estimated using the kipuMarkers approach [17,36].
Genes defining highest traffic nodes and predictive net-
w o r km o d u l e sw e r ea l s ou s e da si n p u t st oc l a s s i f i c a t i o n
models based on logistic regression (Ridge estimator
value: 1.0E-8). Classification performance was summar-
ized with the area under the receiving operating curve
(AUC), and estimated with a leave-one-out cross-valida-
tion procedure (LOOCV). Classification models were
implemented with the Weka system [37]. Inputs to clas-
sifiers were re-scaled so that their means and variances
w e r ee q u a lt o0a n d1r e s p e c t i v e l y .A l s on o t et h a tw e
used the standardised outputs of the logistic regression
classifiers to calculate the AUC values.
Microarray gene expression data generation
We analyzed microarray gene expression profiles from
32 patients with good and poor post-MI clinical out-
come (4 months after MI, 16 patients/category). Good
outcome was defined as the preservation of left ventri-
cular (LV) systolic function and high ejection fraction
(EF) after MI (EF > 40%, median 63%, range 45-73%). A
patient exhibited poor outcome when presenting
impaired LV function and low EF (EF ≤ 40%, median
35%, range 20-40%). Clinical characteristics of patients
selected, microarray data generation and pre-processing
procedures are described in [18].
Experimental verification
We also performed a follow-up experimental replication
using multiplex TaqMan PCR. Out of the 32 RNA sam-
ples extracted from the patients used in the microarray
experiments, 11 samples were available for quantitative
PCR determination. Thus, we measured the gene
expression of key putative biomarkers using this sub-set
of patients (11 patients, 7 with poor clinical outcome) as
a first validation step.
Multiplex TaqMan assay
Total RNA was extracted from 2.5 mL of whole blood
collected the day of MI by the PAXgeneTM technology
and 1 μg of total RNA was reverse transcribed using
SuperScriptTM II Reverse Transcriptase (Invitrogen,
Merelbeke, Belgium) according to the manufacturer’s
protocol. Expression levels of TRAF2 (TNF receptor-
associated factor 2), UBC (ubiquitin C) and SHKBP1
(SH3KBP1 binding protein 1) were assessed by quantita-
tive PCR, in a multiplex TaqMan assay. SF3A1 was cho-
sen as housekeeping gene for normalization. PCR was
performed in a BioRad CFX96™ apparatus using the
following primers and probes: TRAF2 forward primer
GGCTTCTCCAAGACCCTCCTG, TRAF2 reverse pri-
mer TTCGTGGCAGCTCTCGTATTCT, TRAF2 probe
TexasRed-ACTGTGCTGCCTGTGTTCACGAG-BHQ2,
UBC forward primer AGCGAGCGTCCTGATCCTTC,
UBC reverse primer CACCCGGCGCGTCCTTATAT,
UBC probe FAM-AGTAGTCCCTTCTCGGCGATT
CTG-BHQ1, SHKBP1 forward primer GACGGAGCAA-
GAGCTGATGGA, SHKBP1 reverse primer GCTGCGT
TGTTCAAAAGGAAGTTT, SHKBP1 probe HEX-
CCAGGAACTGGTGCGGAGTGG-BHQ2, SF3A1 for-
ward primer AAGGGTCCAGTGTCCATCAAAGT,
SF3A1 reverse primer GCCATGTTGTAGTAAGC-
CAGTGAG, SF3A1 probe Cy5-ACCAGGTCTCTGT-
CATTAAGGTGAAG-BHQ3. The multiplex reaction
was performed on 4 μL of cDNA (previously diluted
10×) in a 20 μL reaction mix containing 1× AmpliTaq
Gold buffer (Applied Biosystems, Halle, Belgium), 5 mM
of MgCl2 (Applied Biosystems), 500 μM of each dNTPs
(Invitrogen), 4 U of AmpliTaq Gold (Applied Biosys-
tems), 400 nM of each TRAF2 primers and probe, 300
nM of each SHKBP1 primers and probe, 1 μM of each
UBC primers, 500 nM of UBC probe and 200 nM of
each SF3A1 primers and probe. The PCR reaction was
composed of 1 cycle at 95°C for 8 min, followed by 60
cycles at 95°C for 30 s, 63.5°C for 30 s and 72°C for 30
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were optimized to allow for multiplex detection. Regres-
sion was used as Ct determination mode for data analy-
sis. Expression of TRAF2, UBC and SHKBP1 genes was
calculated as: gene expression = 2
(Ct SF3A1 - Ct gene).
In order to select the housekeeping gene for this
experiment, we measured the expression of 12 different
known housekeeping genes: ACTB, GAPDH, UBC,
B2M, YWHAZ, SF3A1, 18S rRNA, CYC1, EIF4A2,
SDHA, TOP1 and ATP5B, using the geNorm™ House-
keeping Gene Selection Kit (PrimerDesign). Results indi-
cated that the expression of SF3A1 was the most stable
between samples. We determined the amplification effi-
ciency of each primer pair during the set up of this mul-
tiplex TaqMan qPCR essay: efficiencies varied from
93.1% to 102.8%, depending on the primer pair studied.
This indicated high amplification efficiency for each
gene. Moreover, we compared the expression of each
gene in the multiplex reaction to its expression in a sin-
gleplex reaction. Ct values obtained for each gene were
identical between multiplex and singleplex PCR, indicat-
ing that the multiplex reaction was not rate limiting.
Results
My-Inflamome: A novel resource for inflammation and
post-MI research
My-Inflamome seed set consisted of 415 proteins,
including 28 known biomarkers. Examples of seed pro-
t e i n sa r e :T N F ,C R P ,F A Sa n dT N F R S F 1 0 A .M y - I n f l a -
mome was composed of 2595 proteins and 6181
interactions in total. The single largest, interconnected
network component (island) included 2532 nodes and
6131 interactions (mean number of interactions per
node: 4.25). We focused on this network for subsequent
analyses (Additional file 1). A global view of My-Infla-
mome is displayed in Figure 2. Figure 3 depicts the cor-
relation between node degree and traffic in My-
Inflamome. Examples of known and candidate biomar-
kers are highlighted on the plot. Because of the observed
relatively strong correlation (Spearman correlation, r =
0.93, P = 1E-4) and the previously demonstrated func-
tional importance of high traffic nodes, we concentrated
on top high-traffic proteins in subsequent analyses
(Table 1). We note that none of the top-10 high-traffic
nodes were included in the list of known inflammation
biomarkers in post-MI. On the basis of their traffic
values, standard inflammation biomarkers CRP, IL6 and
TNF ranked 227
th, 478
th and 607
th respectively. This
further indicates that our approach is not biased toward
traditional biomarkers.
My-Inflamome is biologically meaningful
We detected 21 highly-interconnected modules with
diverse sizes and numbers of interactions in My-
I n f l a m o m e( T a b l e2 ) .T h el a r g e s tm o d u l e sa r es t r o n g l y
implicated in post-translational protein modifications
and signal transduction processes (e.g., Modules 5, 10
and 16). Different modules are directly relevant to cell
death and development processes (e.g., Modules 4, 8
and 14). Others appear specialized in immune responses
(e.g., Module 9). Four modules were not statistically
associated with GO BP terms (Modules 11, 12, 17 and
21). Module 1 is specialized in blood coagulation and
wound healing processes. My-Inflamome modules oper-
ate across different cellular regions, including the
nucleus, cytoplasm and the extra-cellular space. How-
ever, 7 modules were not significantly associated with
specific cellular compartments.
Because of the therapeutic and prognostic potential of
these modules, we searched for major interactions
between miRNAs and targets found in each module. We
found statistically detectable evidence that Modules 6, 7
and 16 may be regulated by different miRNAs. For
example, hsa-miR-335*, recently implicated in breast
tumor suppression [38], is substantially linked to targets
in Module 7, which in turn are significantly enriched in
genes with transcriptional regulatory roles. Figure 4
summarizes this functional quantitative characterization
of My-Inflamome modules on the basis of the most sig-
nificant associations observed. Details of module compo-
sition and functional descriptions are available in
Additional file 2.
My-Inflamome guides the discovery of candidate
prognostic biomarkers
To assess the predictive potential of these results, first we
established the capacity of genes encoding high-traffic
proteins and of modules to differentiate prognostic cate-
gories (good vs. poor prognosis). Among the top high-
traffic proteins, IKBKE (inhibitor of kappa light polypep-
tide gene enhancer in B-cells, kinase epsilon), TRAF2
(TNF receptor-associated factor 2) and UBC (ubiquitin
C) were found statistically differentially expressed at the
(nominal) P = 0.02 level (Mann-Whitney U Test). The
modules showing the highest differential (mean) expres-
sions were Module 17 (corrected P = 0.02) and Module
11 (P = 0.06). Note that these modules are not statisti-
cally linked to specific biological processes, and only
Module 11 appears circumscribed to a specific cellular
region (Collagen type VI). Within Module 11, SHKBP1
(SH3KBP1 binding protein 1) is differentially expressed
(Mann-Whitney U Test, nominal P = 0.006).
Motivated by these findings, we evaluated these genes
and modules as inputs to (supervised) computational
prognostic models. Different combinations of genes and
modules were used as inputs to logistic regression mod-
els (Table 3). The highest classification performance
(AUC = 0.84) was obtained when using the individual
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with available microarray data: CD5, PIK3C3, FBXL2,
MIA3, SHKBP1 and ZC3H7A). This was followed by a
model in which the mean expression values of M11 and
M17 were applied as inputs (AUC = 0.8). The combina-
tion of module-derived and high-traffic genes also
offered promising results (TRAF2, SHKBP1 and UBC,
AUC = 0.83).
Replication analyses
To verify the validity of these candidate biomarkers, we
replicated microarray experiments using an independent
Figure 2 My-Inflamome network. A. Global view. B. Modular view.
Azuaje et al. BMC Medical Genomics 2011, 4:59
http://www.biomedcentral.com/1755-8794/4/59
Page 6 of 10platform, quantitative PCR (Methods). In this first fol-
low-up evaluation, we decided to focus on the prognos-
tic signature defined by TRAF2, SHKBP1 and UBC. As
a first classification model verification strategy, we
tested the model derived from the microarray data on
the multiplex PCR data (11 samples). The classification
performance on this dataset was comparable to that
obtained above (AUC = 0.79). In a second verification
strategy, we re-built the classification model on the 11
PCR data samples and estimated its performance using
LOOCV. This evaluation also reported classification
capability comparable to previous performance using
this signature (AUC = 0.77). Although this does not
qualify as an independent evaluation of these potential
novel biomarkers, these results at least suggest that it
is viable to obtain adequate predictive concordance
between prognostic models when tested on different
data generated by independent expression measure-
ment platforms.
Discussion
Significance
Although inflammation biomarkers are useful to support
medical decision-making in the MI setting, the complex-
ity and roles of the global interactions of these proteins
have not been adequately elucidated. This is partly
explained by the lack of systems-based approaches to
bridge clinical (i.e., disease phenotypes) and molecular
information (i.e., different types of omic information).
The rationale for applying integrative, network-driven
approaches is reinforced by the knowledge that the
interactive activity of inflammation proteins may be
functionally critical to multiple biological processes,
which cannot be pinpointed by traditional hypothesis-
driven research. Moreover, such an inflammation inter-
actome is spatially distributed in the cell and subject to
different regulatory control mechanisms acting in a
combinatorial fashion. With an approach solely relying
on traditional hypothesis-driven research or single-
source molecular data, it would be difficult to accurately
establish relevant connections between biomarkers and
their prognostic value, while at the same time providing
adequate mechanistic visualizations. In this paper, we
laid out a foundation to address these challenges and
Figure 3 Correlation between node degree and traffic in My-
Inflamome.
Table 1 Top-10 high-traffic proteins in My-Inflamome.
Protein Degree Traffic
MYC 330 1.10E+06
IKBKE 337 1.08E+06
TRAF6 347 1.03E+06
TP53 192 7.77E+05
EGFR 167 7.26E+05
TRAF2 136 5.13E+05
MAP3K3 164 4.07E+05
IKBKG 142 3.28E+05
GRB2 28 3.08E+05
UBC 33 2.99E+05
Table 2 Topological description of My-Inflamome
modules.
Module NP IntraMI InterMI TotInt MTraffic
1 11 10 8 18 38
21 9 1 8 2 1 3 9 3 6
3 52 52 41 93 102
4 132 153 122 275 262
5 437 587 391 978 872
6 252 268 212 480 502
7 127 148 105 253 252
8 265 317 183 500 528
9 13 15 7 22 24
10 507 1589 610 2199 1012
11 5 4 1 5 8
12 6 5 7 12 10
13 39 49 11 60 82.16
14 65 84 41 125 128
15 118 131 59 190 234
16 460 863 307 1170 918
17 3 2 2 4 4
18 7 6 2 8 12
19 5 4 2 6 8
20 4 3 1 4 6
21 5 4 1 5 8
NP: Number of proteins, IntraMI: Number of intra-module interactions, InterMI:
Number of inter-module interactions, TotInt: Total number of interactions,
MTraffic: Median traffic.
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applications.
The inflammation-related proteins TRAF2, SHKBP1
and UBCs were here associated with clinical outcome
after MI based on a multi-source, functional characteri-
zation of network-derived properties. To accomplish
this, we assembled a new compendium of interacting
proteins that are interrelated, and not limited to known
inflammation biomarkers in post-MI. My-Inflamome
represents by itself a contribution to enable future inde-
pendent investigations.
Despite their established use, standard inflammation
markers are poor predictors of clinical outcome after
MI. Prior to this investigation we did not have evidence
to suggest that known biomarkers would appear as top
high-traffic nodes. Our research indicates that indeed
standard biomarkers do not necessarily act as network
bottlenecks in the inflammation network. This confirms
the known little predictive power of widely-applied
inflammation biomarkers as shown by others and our
previous research. Thus, our results offer a possible
explanation for the lack of predictive capability of tradi-
tional markers: They have limited roles as central med-
iators or coordinators of inflammation responses in MI.
Among these putative biomarkers, SHKBP1 (SH3KBP1
binding protein 1) has not been widely characterized,
though SH3KBP1 (SH3-domain kinase binding protein
1) is known to be implicated in apoptosis. Moreover,
SHKBP1 has not been specifically linked to cardiovascu-
lar disease prior to our study. We found this new rela-
tionship by extracting SHKBP1 from a My-Inflamome
module. Although this module was not statistically asso-
ciated with specific biological processes or even specific
cellular localizations, the combined expression values of
the genes encoding this module’s members showed rela-
tively powerful prognostic capacity. SHKBP1 is over-
expressed in patients with poor prognosis, and can actu-
ally offer relatively good classification performance when
used as a single biomarker (AUC = 0.75, microarray
data). Although not a necessary condition for effective
integrated (multi-gene) classification, relatively strong
differential expression of individual inflammation bio-
markers may add to the potential clinical value of the
Table 3 Summary of classification performance of models
defined by My-Inflamome information.
Model number* Inputs AUC
1 Mean expression values of M11 and M17 0.80
2 Individual expression values of M11 and M17 0.84
3 TRAF2, SHKBP1, UBC 0.83
*Logistic regression classifiers.
Figure 4 Functional characterization of My-Inflamome modules. Most statistically detectable associations with GO BP, CC and microRNAs. In
heat map: P is the probability associated with the functional category observed in each module, colors reflect log-transformed values of P. BP:
biological process, MF: molecular function, CC: cellular component. NA: No statistically detectable association. Modules are numbered as in
Figure 2. The darker the color, the more significant the statistical association.
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cardial injury and the duration of these events largely
determine heart remodelling. Thus, future research
could offer more detailed quantitative relationships
between individual levels of inflammation genes and
their influence on cardiac damage or remodelling.
Inflammation can cause plaque rupture in the coron-
ary arteries, which leads to MI. However, this type of
inflammation is highly localized in the heart. Therefore,
we cannot confer putative causative roles to our pro-
posed circulating biomarkers.
Good classification performance was observed when
replicating results with PCR data obtained from the
same cohort of patients used in the model derivation
phase. These results encourage additional investigations
on independent, larger cohorts.
It is also crucial to indicate that standard clinical
biomarkers, N-terminal pro-brain natriuretic peptide
(NT-pro-BNP) and troponin T, have already been ana-
lyzed on the same (model derivation) cohort here investi-
gated [18]. Prognostic models based on these markers
reported lower performance (LOOCV, AUC < 0.7) than
those obtained here with TRAF2, SHKBP1 and UBC.
An examination of the literature and annotated dis-
ease databases indicates that TRAF2, SHKBP1 and UBC
have not been widely investigated in the context of car-
diovascular disease, and that no quantitative links have
been made to clinical response after MI. Only UBC has
been previously linked to coronary artery disease sever-
ity [39]. Also we detected promising associations
between miRNAs and My-Inflamome that could guide
the design of new prognostic or therapeutic interven-
tions based on “driving” regulatory modulation strate-
gies. Considering that we did not incorporate expression
information of miRNAs, the establishment of such sta-
tistically detectable associations underscores the predic-
tive potential of our approach.
Overall, these observations underline the value of our
approach to uncover potentially clinically relevant asso-
ciations, which can be both novel and unbiased.
Limitations and future research
The level of certainty of our quantitative associations is
constrained by the size of the datasets used in the
model derivation and verification analyses of prognostic
models. Nevertheless, we expect to expand our perfor-
mance estimations and comparisons with alternative
models as more data become available. Moreover, in
this study we showed the feasibility of producing con-
cordant results when using different data generation
platforms.
It may be argued that My-Inflamome does not include
all components with relevant involvement in inflamma-
tion-mediated responses to cardiac injury and remodeling.
We acknowledge that the rate of false negatives may be
reduced by implementing a more inclusive network infer-
ence process, e.g., by expanding the seed set. However, at
this stage we emphasized quality, rather than coverage, to
control the level of potentially spurious or false positive
associations.
The clinical acceptance of new biomarkers firstly
depends on the successful development of larger, inde-
pendent evaluations. Moreover, future assessments
should involve additional comparisons with standard
post-MI biomarkers, including those not directly con-
nected to inflammatory responses (e.g., NT-pro-BNP)
[3]. Future research should incorporate measurements
of standard clinical biomarkers, such as CRP or
TNF-a [2]. To enhance the scientific exploitation of
My-Inflamome and add value to our findings, we also
plan to facilitate their user-friendly access and analysis
via a Web-based interface. Researchers can currently
have full access to My-Inflamome in a text-formatted
file format for non-commercial application (Additional
file 1).
Conclusion
In this research, we demonstrated how an integrative,
network-driven strategy can improve systems-level
mechanistic understanding of inflammation in MI. We
also showed the translation of network-derived informa-
tion into new knowledge with potential applications to
assess prognostic outcome after MI. In particular, we
reported new prognostic associations involving three
genes: TRAF2, SHKBP1 and UBC. Potential clinical
implications of our results, including the proposed bio-
markers, will require independent studies.
Additional material
Additional file 1: My-Inflamome network data.
Additional file 2: Functional modular characterization of My-
Inflamome.
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